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Abstract
Introduction: Proto-oncogene survivin is a member of the inhibitor of apoptosis (IAP) family of proteins. The presence
of serous antibodies against survivin in patients with systemic sclerosis has been previously reported; however, there are
few reports regarding the pathophysiological relationship between survivin and systemic sclerosis. We herein
investigated the expression and function of survivin in SSc patients.
Methods: We performed immunohistochemistry analyses to determine the expression of XIAP, cIAP and survivin in skin
lesions from patients with SSc and non-SSc. The expression levels of survivin in peripheral blood mononuclear cells
(PBMCs) obtained from SSc patients and healthy controls were evaluated using RT-PCR and flow cytometry. Additionally,
the function of survivin was verified with overexpression experiments using monocyte-derived dendritic cells (Mo-DCs).
Results: The expression patterns of both XIAP and cIAP were similar, while only the survivin expression differed between
the SSc and non-SSc skin lesions. Survivin-overexpressing cells were detected in the SSc dermis frequently. The positive
rate of survivin in SSc dermis (64.3 %, 9/14) was higher than that in non-SSc dermis (11.2 %, 1/9). Furthermore, survivin+
cells expressed CD1a, one of the DC markers. Real-time PCR and FACS analyses revealed that the survivin-WT (wild type)
expression levels in PBMCs, in particular CD14+ monocytes, from SSc patients were higher than that from healthy
controls. Additionally, the overexpression experiments showed that survivin-WT-overexpressing CD1a+ Mo-DCs have
the characteristics of promoting cell cycle progression and decreasing apoptotic cells.
Conclusions: These findings suggest that dermal survivin+ CD1a+ cell infiltration may be a potential biomarker of SSc
skin lesions. PBMCs and monocytes from SSc patients also overexpressed survivin; therefore, dermal survivin+ DC may
be derived from peripheral blood monocytes. Additionally, survivin may be involved in dermal CD1a+ DC proliferation
through cell cycle activation and resistance to apoptosis. Survivin may be an important molecule for the pathogenesis
of SSc.
Introduction
Survivin is a member of the inhibitor of apoptosis (IAP)
family of proteins, which is characterized by several baculo-
virus IAP repeat (BIR) domains [1, 2]. It is encoded by the
baculoviral IAP repeat containing 5 (BIRC5) gene on
human chromosome 17q25, which encodes a 16.5 kDa pro-
tein of 142 amino acids. Survivin plays pivotal roles in many
fundamental cellular processes, including cell division and
apoptosis [3], and has been suggested to be involved in
cancer development, progression and resistance to treat-
ment [4]. Survivin is especially expressed during normal
embryonic development and in human cancers, while most
normal differentiated cells do not express survivin [5];
therefore, survivin has attracted attention as a potential
target for cancer therapy [6].
Recently, it has been demonstrated that some auto-
immune diseases (for example, rheumatoid arthritis and
multiple sclerosis) are associated with IAP family proteins
[7, 8]. Systemic sclerosis (SSc) is an autoimmune disease
characterized by fibrosis of the skin and other organs,
obliterative vasculopathy and immunological abnormal-
ities. In 2010, it has been reported that autoantibody
against survivin was detectable in patients with SSc [9].
However, the pathophysiological relationship between SSc
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and IAPs, including survivin, remains unclear. In the
present study, we investigated the expression of IAPs in




This study was conducted at the Dohgo Spa Hospital, Tor-
anomon Hospital, and Ehime University Graduate School
of Medicine, and was approved by the clinical ethics com-
mittees of these institutions. SSc, rheumatoid arthritis
(RA), polymyositis/dermatomyositis (PM/DM), osteoarth-
ritis (OA) patients and healthy volunteers, who were pro-
vided adequate information and signed a written consent
form, were included in this study. Patients who suffered
from cutaneous cancer, hematologic cancer and any cuta-
neous infection were excluded. Clinical data were ob-
tained from medical records. All SSc patients fulfilled the
preliminary American College of Rheumatology (ACR)
criteria for classification in 1980 [10]. Patients with SSc
were divided into those with limited and diffuse diseases
according to a previous report [11]. Interstitial pneumonia
(IP) based on SSc was defined as the change in the bilat-
eral basilar lung portions, which were detected with high-
resolution computed tomography [12]. The definition of
scleroderma renal crisis (RC) was according to a previous
report in 2007 [13]. The existence of pulmonary artery
hypertension (PAH) was demonstrated with echocardiog-
raphy, and subsequent right heart catheterization was per-
formed to confirm the diagnosis [14].
Immunohistochemistry (IHC)
The skin specimens of SSc were collected from the fore-
arms, and those of the control patients were collected
from the forearms or lower legs. Formalin-fixed paraffin-
embedded tissue sections were used for the IHC studies.
The following primary antibodies were employed: anti-
XIAP (rabbit polyclonal, Abcam, Tokyo, Japan), anti-cIAP
(cIAP1 and cIAP2) (mouse monoclonal, clone number
681724, R&D Systems, Minneapolis, MN, USA), anti-
survivin (rabbit polyclonal, R&D Systems), anti-survivin-
ΔEx3 (rabbit polyclonal, Abcam), anti-survivin-2B (rabbit
polyclonal, Abcam), anti-CD1a (mouse monoclonal, clone
7A7, Abcam), anti-CD4 (mouse monoclonal, clone
CRRY77, eBioscience, Affymetrix Japan K.K., Tokyo,
Japan) and anti-CD69 (rabbit polyclonal, Bioss, Woburn,
MA, USA). Following deparaffinization and antigen re-
trieval in citrate buffer (pH 6.0), the specimens were incu-
bated with primary antibodies followed by horseradish
peroxidase (HRP)-conjugated secondary antibodies and
then visualized with the 3-amino-9-ethylcarbazole (AEC)
+ kit (Agilent Technologies Dako, Tokyo, Japan). Multiple
immunofluorescence staining was also conducted using
an indirect method with Alexa Fluor-conjugated
secondary antibodies (Invitrogen, Thermo Fisher Scien-
tific, Yokohama, Japan). The slides were also stained with
hematoxylin, Hoechst 33342 or 4′,6-diamidino-2-pheny-
lindole, dihydrochloride (DAPI). The fluorescence was
captured with an Olympus FV1000D laser scanning
microscope (Olympus, Tokyo, Japan) and a Leica 6000E
microscope (Leica microsystems, Tokyo, Japan).
Enzyme-linked immunosorbent assay (ELISA)
Three types of SSc-specific autoantibodies (anti-topoisom-
erase I (Scl-70), anti-centromere and anti-RNA polymerase
III (RNAPIII)) were measured with MESACUP ELISA kits
(Medical & Biological Laboratories, Nagoya, Japan). For the
detection of serum anti-survivin immunoglobulin G (IgG)
antibody, an ELISA was performed as previously described
[9]. Briefly, 96-well plates were coated with glutathione S-
transferase (GST) fusion recombinant proteins of survivin-
wild type (WT) (1,000 ng/ml), which were prepared as pre-
viously reported [15]. The wells were blocked with Blocking
One P (Nacalai Tesque, Kyoto, Japan). Serum samples were
diluted 1:100 in Tris-buffered saline (TBS) containing
Blocking One P and added to the wells. After incubation
and washing, alkaline phosphatase-conjugated goat anti-
human IgG antibody was added. Following additional
washing, p-nitrophenyl phosphate (Pierce, Thermo Fisher
Scientific, Waltham, MA, USA) was added and measured
at 405 nm on a spectrophometer. The mean + 2SD (stand-
ard deviation) among the healthy controls (HCs) (n = 15,
data not shown) was defined as the cutoff value for anti-
survivin IgG antibody.
Reverse transcription polymerase chain reaction (RT-PCR)
and real-time PCR
Peripheral blood mononuclear cells (PBMCs) from SSc
patients and HCs were enriched using Ficoll-Paque
PLUS (GE Healthcare, Tokyo, Japan). Total RNA of the
PBMCs or cultured cells was extracted and purified
using TRIzol (Invitrogen) followed by cDNA synthesis
using a PrimeScript RT Reagent Kit with a gDNA Eraser
(Takara-Bio, Shiga, Japan). Quantitative real-time PCR
using TaqMan probes (FAM/TAMRA) and SYBR Green
was executed in triplicate using the ABI Prism 7500
Real-Time PCR system (Applied Biosystems, Thermo
Fisher Scientific, Yokohama, Japan). The HL-60 cell line
was used as a positive control for RT-PCR. The primer
pairs and probes for amplification of human BIRC5 vari-
ants and hypoxanthine-guanine phosphoribosyltransfer-
ase (HPRT) were described previously [15]. The
upstream and downstream primer sequences used for
interleukin (IL)-6 were 5′-GAGAAAGGAGACATGTA
ACAAGAGT-3′ and 5′-GCAAGTCTCCTCATTGAAT
CCA-3′, respectively. The upstream and downstream
primer sequences for IL-12B were 5′-CCAGAGCAA
GATGTGTCAC-3′ and 5′-CTACGACATAAACATC
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TTTCTTCAG-3′, respectively. The expression of human
HPRT was evaluated as a housekeeping gene to normalize
the ΔCt values. The relative expressions of the target
genes were obtained using the difference in the compara-
tive threshold (ΔΔCt) method.
Fluorescence-activated cell sorting (FACS)
A flow cytometric analysis was performed using the
FACSCalibur and LSRFortessa platforms (BD Biosciences,
Tokyo, Japan). For Ki-67 and 7-amino-actinomycinD (7-
AAD) staining, the FOXP3 Staining Buffer Set
(eBioscience) was used. Antibodies conjugated with FITC,
PerCP or APC were used. Anti-human CD14 (clone
MφP9), anti-human CD45 (clone 2D1) antibodies and 7-
AAD were purchased from BD Biosciences. Anti-human
CD1a (clone HI149), anti-human Ki-67 (clone Ki-67) anti-
bodies and Fixable Viability Dye (FVD520) were obtained
from eBioscience. The cells were washed and stained. For
intracellular staining of survivin and its splice variants,
normal rabbit IgG (Santa Cruz Biotechnology, TX, USA),
anti-survivin (rabbit polyclonal, R&D Systems), anti-
survivin-ΔEx3 (rabbit polyclonal, Abcam), and anti-
survivin-2B (rabbit polyclonal, Abcam) were labeled using
the Zenon Rabbit IgG Labeling Kit (Alexa Fluor 647, Invi-
trogen). The FOXP3 Staining Buffer Set (eBioscience) was
used for fixation and permeabilization. A survivin-WT-
specific antibody was not available, therefore, the mean
fluorescence intensity (MFI) of the estimated survivin-WT
expression level was calculated from other MFI parame-
ters as follows: (survivin-WT) = (survivin (total) – normal
IgG) – (survivin-ΔEx3 – normal IgG) – (survivin–2B
– normal IgG).
Preparation of monocyte-derived dendritic cells (Mo-DCs)
Human monocytes were purified with biotin-conjugated
anti-CD14 antibody (clone 61D3, eBioscience) and strep-
tavidin microbeads (Miltenyi Biotec, Tokyo, Japan) from
PBMCs, which were enriched using Ficoll-Paque PLUS
(GE Healthcare). CD14+ monocytes isolation resulted in
>95 % pure population. Mo-DCs were generated by cul-
turing CD14+ monocytes in RPMI1640 medium supple-
mented with 10 % fetal bovine serum (Gibco, Thermo
Fisher Scientific, Yokohama, Japan), 200 ng/ml rhIL-4
(R&D Systems) and 200 ng/ml rhGM-CSF (Wako
Junyaku Kogyo, Tokyo, Japan). After 5 days of culture,
CD1a+CD14− Mo-DCs (>95 % CD1a+ purity) were
harvested for use.
Transfection for dendritic cells (DCs)
The transfection of in vitro transcribed (IVT) messenger
RNA (mRNA) for DCs was performed using Lipofecta-
mine MessengerMAX Transfection Reagent (Invitrogen).
To generate templates for IVT mRNA, we developed
the pcDNA3-A(124) vector plasmid and BIRC5-inserted
vector plasmids from artificial custom genes, according to
a protocol described previously [16, 17]. The transcription
of pcDNA3-A(124)-based plasmids was performed with
the mMESSAGE mMACHINE T7 transcription Kit
(Ambion, Thermo Fisher Scientific, Yokohama, Japan).
After in vitro transcription, mRNA was purified using the
MEGAclear Kit (Ambion).
Western blot
Cell lysates and recombinant proteins were processed using
SDS-PAGE and Western blotting according to the standard
procedures. The blotted membranes were incubated with
anti-actin (mouse monoclonal, clone AC-15, Invitrogen)
and anti-survivin antibodies followed by HRP-conjugated
secondary antibodies (Jackson ImmunoResearch Inc., West
Grove, PA, USA). The GST-fusion recombinant proteins of
survivin variants were prepared as previously reported [15].
Statistical analysis
The significance in the differences between the two
groups was determined using an unpaired t test, the
Mann–Whitney U test or the chi-square test. The data pro-
cessing and analyses were conducted using the Microsoft
Excel software program (Microsoft, Tokyo, Japan).
Results
The expression of IAPs and survivin in SSc skin lesions
detected with IHC
We first investigated the expressions of several IAP pro-
teins in SSc and non-SSc skin lesions using IHC. The ex-
pression patterns of both XIAP and cIAP were similar
(Fig. 1a-d), while only the survivin expression differed
between SSc and non-SSc skin lesions (Fig. 1e-f).
Survivin-overexpressing cells were detected in SSc dermis
frequently. Subsequently, we performed the IHC analyses
using anti-survivin antibodies on skin specimens obtained
from 14 SSc patients and nine non-SSc patients (five cases
of RA, one case of PM/DM and three cases of OA).
Survivin-positive small cells were detected in the SSc der-
mal lesions. These cells were detected in the SSc dermis
in 64.3 % of the cases (9/14), while they were rarely de-
tected in the dermis from non-SSc patients (11.1 %, 1/9
cases) (p = 0.017) (Fig. 2a) (Table 1). Moreover, the rate of
the coexistence of organ involvement in dermal survivin-
positive SSc patients (62.5 %, 6/9) (three cases with inter-
stitial pneumonia (IP), two cases with renal crisis (RC)
and one case with coexisting RC and pulmonary artery
hypertension (PAH)) was higher than that in dermal
survivin-negative SSc patients (0 %, 0/5) (p = 0.028). Con-
sequently, the dermal survivin may be a potential diagnos-
tic marker of SSc with organ derangement.
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CD1a+ survivin+ cells in dermal lesions from SSc patients
Moreover, we determined the type of cells expressing
survivin. The survivin-positive cells in the SSc dermis
expressed CD1a antigen, one of the dendritic cell (DC)
markers, using the multiple immunofluorescence method
(Fig. 2b). Therefore, survivin in the SSc dermal lesions
was expressed in CD1a+ DCs. Moreover, activated T lym-
phocytes (CD69+CD4+cells) existed around the CD1a+
cells (Fig. 2c-d).
The survivin expression levels in PBMCs from SSc patients
Human dermal DCs mainly divide into two subsets:
CD1a+ and CD14+ [18]. Conventional dermal DCs mainly
develop from blood-derived DC precursors, in particular
monocytes [19]. Therefore, we investigated the survivin
expression levels of PBMCs and CD14+ cells from SSc
patients and healthy controls (HCs). In these experiments,
we collected PBMCs from SSc patients with IP and/or
other organ involvement (Table 2), because many of the
SSc patients with dermal survivin expression had organ
derangement (Table 1).
It was reported that the BIRC5 gene could generate
survivin splice variants, which result from alternative
splicing (Fig. 3a) [20]. RT-PCR revealed that the expres-
sions of survivin-WT, -ΔEx3 and -2B were detectable in
PBMCs from SSc patients (n = 5) and HCs (n = 5)
(Fig. 3b). Subsequently, we performed quantification of
the survivin splicing variants using real-time PCR. As a
result, the expression levels of only survivin-WT in
PBMCs from SSc patients were higher than those from
the controls (p = 0.016) (Fig. 3c). There were no significant
differences in the expression levels of survivin-ΔEx3
or -2B. Moreover, we also measured the intracellular
expression levels of survivin proteins in PBMCs using
flow cytometry. As shown in Fig. 3d, flow cytometry
using anti-survivin antibody, which can detect all survivin
variants (Fig. 2e), revealed that the survivin expression
levels in monocytes from SSc patients (CD45+CD14+
cells) were higher than those from HCs (Fig. 3d). However,
Fig. 1 Immunohistochemistry (IHC) staining of XIAP, cIAP and survivin in systemic sclerosis (SSc) dermal lesions. SSc (a, c, e) and non-SSc (b, d, f) skin
lesions evaluated with IHC (all stained by red, ×20). The SSc patients were designated numbers 4, 6, 7, and 12 in Table 1 (n = 4). A case of rheumatoid
arthritis (RA), a case of polymyositis/dermatomyositis (PM/DM) and two cases of osteoarthritis (OA) were included among the non-SSc patients (n = 4).
a, b XIAP. c, d cIAP. e, f survivin. Representative images are shown. In the dermis of SSc, many survivin-positive cells were detected (arrows)
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the expression levels of survivin-ΔEx3 and -2B in CD45
+CD14+ cells were similar between SSc patients and HCs.
The estimated survivin-WT expression levels of CD45
+CD14+ cells in SSc patients (n = 3) were higher than
those in HCs (n = 4) (p = 0.043) (Fig. 3e).
These results did not contradict the IHC data for SSc
dermal lesions, in which survivin-ΔEx3 or survivin-2B
were not detected (Fig. 2f ). Accordingly, these data
suggest that survivin-WT is expressed in PBMCs, in
particular CD14+ monocytes, and dermal CD1a+ DCs
derived from PBMCs also express survivin-WT in SSc
patients.
Survivin-WT promotes cell proliferation in CD1a+ Mo-DCs
CD1a+ DCs can be generated from PBMCs by culturing
in vitro [21] (Fig. 4a). We obtained Mo-DCs from healthy
Fig. 2 The characteristics of survivin expression in systemic sclerosis (SSc) dermal lesions. a Arrows indicate survivin-positive cells (stained by red). (b-d)
The multiple immunofluorescence method for SSc and non-SSc dermal lesions with anti-survivin, anti-CD1a, anti-CD4 and anti-CD69 antibodies was
performed. b Arrows indicate CD1a+ survivin+ cells. c Staining with anti-CD1a, anti-CD69 antibodies. d Staining with anti-CD4 and anti-CD69 antibodies.
Arrows indicate CD69+ CD4+ cells. e A Western blot analysis revealed that the anti-survivin antibody reacted to all three variants. On the other hand,
anti-survivin-ΔEx3 and anti-survivin-2B antibodies reacted with each respective variant only. f Immunohistochemistry (IHC) using anti-survivin-ΔEx3
and -2B antibodies (stained by red). Right figures show positive controls on the same slide
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donors, established a transfection method (Fig. 4b), and
investigated the function of overexpressed survivin. We
selected survivin-WT among the splice variants, according
to the results from PBMCs and IHC studies (as mentioned
above). When Mo-DCs were transfected to overexpress
survivin at day 0 (Fig. 4c), survivin overexpression did not
affect the differentiation of DCs until 50 hours.
Using these systems, we investigated the role of survi-
vin in CD1a+DCs. CD1a+ Mo-DCs were transfected to
overexpress survivin at day 5. As a result, the Ki-67-
positive rates, which reflect cell cycle progression, of
survivin-overexpressing CD1a+ Mo-DCs were higher
than those of controls (p = 0.019) (Fig. 4d). These cells
were then stained with 7-AAD, which indicates cell
cycling and DNA fragmentation. This analysis revealed
that the rates of G2/M phase cells among the survivin-
overexpressing DCs was higher than those among con-
trol cells (p = 0.034), and the rates of apoptotic cells
among survivin-overexpressing DCs was lower than con-
trols (p = 0.004). In conclusion, survivin-WT may be in-
volved in CD1a+ Mo-DC proliferation through cell cycle
activation and resistance to apoptosis. There were no
significant differences in the expression levels of IL-6
and IL-12B between survivin-overexpressing DCs and
controls (data not shown).
Discussion
The pathological features of SSc skin lesions are a thin
epidermis and thick dermis [22]; therefore, the dermal
lesions of SSc may be noteworthy. On the other hand,
Koike et al. reported that the levels of survivin proteins
and autoantibodies against survivin were elevated in sera
of SSc patients [9]. However, previous reports on the
relationship among SSc, survivin and dermal DCs have
been limited. In the present study, we detected the survi-
vin expression in dermal lesions and PBMCs from SSc

















1 70s Female 10 Limited + - + - - - +
2 60s Male 0.3 Limited + - + - - - +
3 70s Female 0.3 Diffuse + + - - - - +
4 50s Female 1 Limited + - - - - + -
5 40s Female 2 Limited - - - - - - -
6 40s Female 0.5 Limited - - - - - - -
7 60s Female 0.5 Limited - - - - - - -
8 70s Female 2 Limited + - - - - + -
9 60s Female 9 Limited + + - - - + -
10 40s Female 1 Limited + - - - - - -
11 60s Male 0.5 Limited - - - - - - -
12 60s Female 5 Limited + + - - - + -
13 40s Female 7 Diffuse + - + + - - +
14 60s Female 3 Limited - - - - + - -
SSc systemic sclerosis, IHC immunohistochemistry, IP interstitial pneumonia, RC renal crisis, PAH pulmonary artery hypertension, Scl-70 topoisomerase I, RNAPIII
RNA polymerase III














(serum, IgG)Scl-70 Centromere RNAPIII
1 70s Female 19 Diffuse + - + + - - -
2 80s Female 4 Limited + - - - - - +
3 50s Female 2 Diffuse + - + - - - +
4 50s Female 22 Diffuse + - - + - - +
5 50s Male 22 Diffuse + + + - - + +
SSc systemic sclerosis, PBMCs peripheral blood mononuclear cells, IP interstitial pneumonia, RC renal crisis, PAH pulmonary artery hypertension, Scl-70
topoisomerase I, RNAPIII RNA polymerase III, IgG immunoglobulin G
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patients. The dermal survivin expression were observed
especially in SSc patients with organ involvement. There-
fore, we believe that survivin may be an attractive bio-
marker of SSc with organ derangement. For the detection
of survivin expression in SSc patients, dermal IHC stain-
ing is a predominant method of choice. However,
malignant tumor invasion, viral infections (e.g., herpes
virus) or postoperative granulation tissue often express
survivin in dermal lesions, which may lead to false positive
results.
Survivin+ dermal cells also expressed CD1a, which is one
of the DC markers. CD1a protein is a family of major
Fig. 3 The expression levels of survivin splice variants in peripheral blood mononuclear cells (PBMCs) from systemic sclerosis (SSc) patients. a The
scheme of survivin splice variants. BIRC5 gene could generate several splice variants. b The reverse transcription polymerase chain reaction (RT-PCR)
analysis of PBMCs from healthy controls (HCs) (n = 5) and SSc patients with interstitial pneumonia (IP) (n = 5). The figure shown is representative of
the samples. c Relative expression levels of survivin (-WT, -ΔEx3 and -2B) in PBMCs from HCs (n = 5) and SSc patients (n = 5) using real-time PCR.
*Mann–Whitney U test, p < 0.05. d PBMCs were collected from HCs (n = 4) and SSc patients (n = 3), and fluorescence-activated cell sorting (FACS)
analyses were performed for the measurement of intracellular survivin expression. The SSc patients were designated as numbers 1, 3 and 5 in Table 2.
Stained PBMCs were gated using the forward and side scatters and CD45+CD14+ cells were analyzed (gray line, normal immunoglobulin G (IgG) control;
green line, HC; red line, SSc). Representative images and their mean fluorescence intensity (MFI) are shown. e Estimated survivin-wild type (WT)
expression levels of peripheral CD45+CD14+ cells in HCs (n = 4) and SSc patients (n = 3). Mean ± SEM, *t test, p < 0.05
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Fig. 4 The role of survivin in CD1a+ monocyte-derived dendritic cells (Mo-DCs). a CD14+ monocytes change into CD1a+CD14− DCs by culturing with
granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4. b A Western blot analysis showed that BIRC5 mRNA expressed the
survivin-WT protein in Mo-DCs. c Mo-DCs were transfected with survivin-wild type (WT) and mock at day 0, and were subsequently stimulated with
GM-CSF and IL-4. At 25 and 50 hours, the samples were analyzed using fluorescence-activated cell sorting (FACS) analyses. The percentages in the figures
indicate the ratio of CD1a+CD14− cells. d-f Mo-DCs were transfected with survivin-WT and mock at day 6, and the following FACS analyses were performed
at 24 hours. d Harvested Mo-DCs were stained with FVD520 and anti-Ki-67 antibodies. The positive rate was calculated as the number of Ki-67-positive cells
among FVD520-negative (living) cells. Data are presented as the percentage of control cells. Mean ± SEM. n = 4 (both groups). *t test, p< 0.05. e, f
Harvested Mo-DCs were stained with 7-amino-actinomycinD (7-AAD). The percentages of G2/M phase cells (e) and apoptotic cells (f) were calculated.
Data are presented as the percentage of control cells. Mean ± SEM, n = 5 (both groups). t test, *p< 0.05, **p< 0.01
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histocompatibility complex (MHC) class I-like antigen-
presenting molecules, which can combine with β-2-
microglobulin and some apolar oil antigens and react to the
CD1a-reactive αβT cell receptor [23]. CD1a-autoreactive T
lymphocytes tend to home in on the skin and produce
cytokines (for example, interferon (IFN)-γ, IL-22, etc.) [24].
Although CD1a+ DCs rarely exist in the normal dermis
[25], many CD1a+ DCs existed in the SSc dermal lesions.
Moreover, activated lymphocytes (CD69+CD4+) existed
around these cells. According to our presented data, we
speculate that CD1a+ survivin+ cells may induce an im-
munological reaction in the SSc dermal lesion.
A genome-wide association study (GWAS) showed that
IRF8 (interferon regulatory factor 8) gene was associated
with SSc [26]. IRF8 is expressed at very high levels in
mononuclear phagocytes and regulates granulocyte/
macrophage differentiation and DC development in
mouse models [27–30]. In humans, autosomal recessive
IRF8 deficiency induces Mendelian susceptibility to myco-
bacterial disease (MSMD) [31]. In these patients, CD11c+
myeloid DCs or CD123+ plasmacytoid DCs could not be
detected in the blood, and CD1a+ DCs were also not de-
tected in the dermis. Therefore, some pathophysiological
relationship may exist between DCs and SSc.
Conventional dermal DCs mainly develop from blood-
derived DC precursors, in particular monocytes [19].
We speculate that PBMCs have a potential as DC pre-
cursors. We subsequently performed experiments to
determine the expression levels of survivin in PBMCs
from SSc patients using RT-PCR (mRNA expression)
and FACS (protein expression). The BIRC5 gene can
generate several survivin variants, as noted above [20],
and three variants (survivin-WT, -ΔEx3 and -2B) were
dominantly expressed. However, survivin-WT-specific
antibody could not be developed, because all amino acid
sequences of survivin-WT were included in survivin-2B.
As shown in Fig. 2e, the anti-survivin antibody used in
our presented experiments reacts to all three variants.
As an alternative method of survivin-WT protein ana-
lysis, we calculated the estimated survivin-WT expres-
sion levels using other parameters. The results of our
FACS analysis demonstrated no difference in the expres-
sion levels of survivin-ΔEx3 or -2B, whereas survivin-
WT was overexpressed in PBMCs (in particular CD14+
cells) from SSc patients compared with HCs. Moreover,
the fact that neither survivin-ΔEx3 nor -2B was detected
in SSc dermal lesions also supported the significance of
survivin-WT expression. We believe that dermal survivin-
WT+ DCs in SSc may be derived from peripheral blood
monocytes.
Subsequently, we investigated the function of survivin-
WT in CD1a+ DCs using in vitro cultured Mo-DCs.
These experiments showed that survivin-WT could
induce cell cycle activation and apoptosis inhibition in
CD1a+ Mo-DCs. Therefore, we speculate that the role of
survivin-WT in dermal CD1a+ DCs is cell proliferation
through cell cycle activation and resistance to apoptosis.
Conclusions
Our findings suggested that dermal survivin+ CD1a+ cell
infiltration may be a potential biomarker of SSc skin
lesions. PBMCs and monocytes from SSc patients also
overexpressed survivin, therefore, dermal survivin+ DC
may be derived from peripheral blood monocytes. Fur-
thermore, survivin-WT could be involved in CD1a+ DC
proliferation through cell cycle activation and resistance
to apoptosis. Survivin may be an important molecule for
the pathogenesis of SSc.
Abbreviations
7-AAD: 7-amino-actinomycinD; AEC: 3-amino-9-ethylcarbazole;
BIR: baculovirus IAP repeat; BIRC5: baculoviral IAP repeat containing 5;
DAPI: 4′,6-diamidino-2-phenylindole, dihydrochloride; DC: dendritic cell;
ELISA: enzyme-linked immunosorbent assay; FACS: fluorescence-activated cell
sorting; GM-CSF: granulocyte macrophage colony-stimulating factor;
GST: glutathione S-transferase; GWAS: genome-wide association study;
HC: healthy control; HPRT: hypoxanthine-guanine phosphoribosyltransferase;
HRP: horseradish peroxidase; IAP: inhibitor of apoptosis; IgG: immunoglobulin
G; IHC: immunohistochemistry; IL: interleukin; INF: interferon; IP: interstitial
pneumonia; IRF8: interferon regulatory factor 8; IVT: in vitro transcribed;
MFI: mean fluorescence intensity; MHC: major histocompatibility complex;
Mo-DC: monocyte-derived dendritic cell; mRNA: messenger RNA;
MSMD: Mendelian susceptibility to mycobacterial disease; OA: osteoarthritis;
PAH: pulmonary artery hypertension; PBMC: peripheral blood mononuclear
cell; PM/DM: polymyositis/dermatomyositis; RA: rheumatoid arthritis; RC: renal
crisis; RNAPIII: RNA polymerase III; RT-PCR: reverse transcription polymerase
chain reaction; Scl-70: topoisomerase I; SSc: systemic sclerosis;
TBS: Tris-buffered saline; WT: wild type.
Competing interests
The author(s) declare that they have no competing interests.
Authors’ contributions
SM designed the research, collected samples from human subjects, carried out
all experiments, analyzed the data and wrote the manuscript. TM designed the
research, carried out the dermal imaging studies and was involved in drafting
of the manuscript. YU and KT collected samples from human subjects, analyzed
the data and were involved in drafting of the manuscript. MK and ES designed
the research and were involved in drafting of the manuscript. JM carried out
the PBMCs study and the pathological assessment and was involved in drafting
of the manuscript. All authors read and approved the manuscript.
Acknowledgments
We thank N. Arita, Division of Analytical Pathology, Ehime University Graduate
School of Medicine, Toon, Japan, and T. Fujii, Department of Pathology,
Toranomon Hospital, Tokyo, Japan, for their valuable assistance with preparation
of the skin serial sections. We also thank M. Kimura, Department of Infectious
Diseases, Toranomon Hospital, Tokyo, Japan, and Y. Saeki, Department of Clinical
Laboratory, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama,
Japan, for collecting the patients’ data. We thank the staff of the Analysis Center
of Life Science, Hiroshima University for FACS analyses. Written informed consent
was obtained from the patient for publication of their individual details and
accompanying images in this manuscript. The consent form is held by the
authors’ institution and is available for review by the Editor-in-Chief. Funding
statement: this work was partially supported by JSPS KAKENHI grant number
26293232 to J.M. and was partially supported by JSPS KAKENHI grant number
26500010 and the JST/AMED-SENTAN Program and JST/AMED-CREST, Life
Innovation Grant to MK.
Mokuda et al. Arthritis Research & Therapy  (2015) 17:275 Page 9 of 10
Author details
1Department of Immunology, Graduate School of Biomedical and Health
Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551,
Japan. 2Department of Pathology, Ehime University Proteo-Science Centre
and Graduate School of Medicine, Shizukawa, Toon, Ehime 791-0295, Japan.
3Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo
Spa Hospital, 21-21 Otsu Dohgo-Himezuka, Matsuyama, Ehime 790-0858,
Japan. 4Department of Clinical Immunology and Rheumatology, Hiroshima
University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
5Nephrology Center and the Okinaka Memorial Institute for Medical
Research, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470,
Japan.
Received: 18 May 2015 Accepted: 9 September 2015
References
1. Birnbaum MJ, Clem RJ, Miller LK. An apoptosis-inhibiting gene from a nuclear
polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs.
J Virol. 1994;68:2521–8.
2. Borden KL, Freemont PS. The RING finger domain: a recent example of a
sequence-structure family. Curr Opin Struct Biol. 1996;6:395–401.
3. Altieri DC. Survivin and IAP proteins in cell-death mechanisms.
Biochem J. 2010;430:199–205.
4. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin,
expressed in cancer and lymphoma. Nat Med. 1997;3:917–21.
5. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis
(IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–59.
6. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer.
2003;3:46–54.
7. Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin,
a key member of the apoptosis inhibitor family, and its specific antibodies
determines erosivity in rheumatoid arthritis. Arthritis Res Ther.
2005;7:R349–58.
8. Sharief MK, Semra YK. Heightened expression of survivin in activated T
lymphocytes from patients with multiple sclerosis. J Neuroimmunol.
2001;119:358–64.
9. Koike Y, Muroi E, Yoshizaki A, Ogawa F, Yanaba K, Takenaka M, et al.
Autoantibody against survivin in patients with systemic sclerosis. J Rheumatol.
2010;37:1864–70.
10. Subcommittee for scleroderma criteria of the American Rheumatism
Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria
for the classification of systemic sclerosis (scleroderma). Arthritis Rheum.
1980;23:581–90.
11. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA, et al.
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.
J Rheumatol. 1988;15:202–5.
12. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A,
et al. 2013 classification criteria for systemic sclerosis: an American College
of Rheumatology/European League against Rheumatism collaborative
initiative. Arthritis Rheum. 2013;65:2737–47.
13. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al.
Scleroderma renal crisis: patient characteristics and long-term outcomes.
QJM. 2007;100:485–94.
14. Saggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA, et al.
Exercise-induced pulmonary hypertension associated with systemic
sclerosis: four distinct entities. Arthritis Rheum. 2010;62:3741–50.
15. Mokuda S, Miyazaki T, Ito Y, Satoshi Y, Hiroko I, Yun G, et al. The proto-oncogene
survivin splice variant 2B is induced by PDGF and leads to cell proliferation in
rheumatoid arthritis fibroblast-like synoviocytes. Sci Rep. 2015;5:9795.
16. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, et al.
Modification of antigen-encoding RNA increases stability, translational efficacy,
and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108:4009–17.
17. Landi A, Babiuk LA. van Drunen Littel-van den Hurk S. High transfection
efficiency, gene expression, and viability of monocyte-derived human
dendritic cells after nonviral gene transfer. J Leukoc Biol. 2007;82:849–60.
18. Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization
of dermal dendritic cells obtained from normal human skin reveals
phenotypic and functionally distinctive subsets. J Immunol.
1993;151:6535–45.
19. Malissen B, Tamoutounour S, Henri S. The origins and functions of dendritic
cells and macrophages in the skin. Nat Rev Immunol. 2014;14:417–28.
20. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3
and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin
with different antiapoptotic properties. Cancer Res. 1999;59:6097–102.
21. Cao X, Sugita M, Van Der Wel N, Lai J, Rogers RA, Peters PJ, et al. CD1
molecules efficiently present antigen in immature dendritic cells and traffic
independently of MHC class II during dendritic cell maturation. J Immunol.
2002;169:4770–7.
22. Mori Y, Kahari VM, Varga J. Scleroderma-like cutaneous syndromes.
Curr Rheumatol Rep. 2002;4:113–22.
23. de Jong A, Cheng TY, Huang S, Gras S, Birkinshaw RW, Kasmar AG, et al.
CD1a-autoreactive T cells recognize natural skin oils that function as
headless antigens. Nat Immunol. 2014;15:177–85.
24. de Jong A, Peña-Cruz V, Cheng TY, Clark RA, Van Rhijn I, Moody DB.
CD1a-autoreactive T cells are a normal component of the human αβ T cell
repertoire. Nat Immunol. 2010;11:1102–9.
25. Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA. Normal
human dermis contains distinct populations of CD11c + BDCA-1+ dendritic
cells and CD163 + FXIIIA+ macrophages. J Clin Invest. 2007;117:2517–25.
26. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, et al.
Identification of novel genetic markers associated with clinical phenotypes
of systemic sclerosis through a genome-wide association strategy.
PLoS Genet. 2011;7:e1002178.
27. Aliberti J, Shulz O, Pennington DJ, Tsujimura H. Reis e Sousa C, Ozato K,
et al. Essential role for ICSBP in the in vivo development of murine
CD8alpha + dendritic cells. Blood. 2003;101:305–10.
28. Schiavoni G, Mattei F, Sestili P, Borghi P, Venditti M, Morse 3rd HC, et al.
ICSBP is essential for the development of mouse type I interferon-producing
cells and for the generation and activation of CD8alpha(+) dendritic cells.
J Exp Med. 2002;196:1415–25.
29. Tailor P, Tamura T, Morse 3rd HC, Ozato K. The BXH2 mutation in IRF8
differentially impairs dendritic cell subset development in the mouse. Blood.
2008;111:1942–5.
30. Tsujimura H, Tamura T, Ozato K. Cutting edge: IFN consensus sequence
binding protein/IFN regulatory factor 8 drives the development of type I
IFN-producing plasmacytoid dendritic cells. J Immunol. 2003;170:1131–5.
31. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J,
et al. IRF8 mutations and human dendritic-cell immunodeficiency.
N Engl J Med. 2011;365:127–38.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mokuda et al. Arthritis Research & Therapy  (2015) 17:275 Page 10 of 10
